Advanced Solid Tumor
Conditions
Keywords
advanced solid tumor, standard treatment failure, radiotherapy, immunotherapy
Brief summary
The goal of this clinical trial is to find a new radioimmunotherapy regimen for advanced malignancies with multiple metastatic after standard treatment failure/drug resistance. The main questions it aims to answer is: the safety and efficacy of the new regimen for advanced multiple metastatic solid tumors standard treatment failure/drug resistance, and explore the impact on immune function. Participants will receive the combination of radiotherapy and immunotherapy.
Detailed description
More effective treatment regimens remain to be explored for advanced malignancies with multiple metastatic after standard treatment failure/drug resistance. The combination of radiotherapy and immunotherapy is considered to be a promising therapeutic strategy. Studies showed the efficacy of PRaG (PD-1 inhibitor, Radiotherapy and GM-CSF) treatment and stereotactic radiotherapy (SBRT) combined with low-dose radiotherapy (LDRT) for advanced tumors. Therefore, the investigators designed a new radioimmunotherapy regimen, including SBRT, LDRT , PD-1/PD-L1 inhibitor, and GM-CSF. This study aimed to evaluate the safety and efficacy of the new regimen for advanced multiple metastatic solid tumors standard treatment failure/drug resistance, and explore the impact on immune function.
Interventions
COMBINATION_PRODUCTRadiotherapy combined with immunotherapy
(1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
Sponsors
China-Japan Friendship Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. advanced malignant solid tumors with multiple metastases or relapses, with pathological diagnosis or medical record; 2. disease progression or recurrence after standard treatment, or unsuitable/intolerable for standard treatment, or rejection of standard treatment due to personal willingness; 3. patients with disease progression or drug resistance after previous immunotherapy are allowed to be included; a history of radiotherapy in the LDRT area or other sites is allowed to be included, provided that there are no residual toxic effects; 4. at least ≥1 lesion suitable for SBRT, and ≥1 lesion suitable for LDRT, and the above lesions must be measured; 5. no contraindications to radiotherapy; 6. Eastern Cooperative Oncology Group (ECOG) score: 0-2 points, and life expectancy \>3 months; 7. important organ function is acceptable, defined as: white blood cells ≥3.0×10\^9/L, platelets ≥75×10\^9/L, hemoglobin ≥90g/L, glutamic pyruvic transaminase and glutamic oxalacetic transaminase ≤2.5 times the upper limit of normal value, serum creatinine \< 178μmol/L; 8. voluntary participation and sign the informed consent.
Exclusion criteria
1. no suitable lesions for radiotherapy, or the limit of important organs at risk could not be met; 2. permanent discontinuation of PD-1/L1 inhibitors due to ≥ grade 3 immune-related toxic reactions; 3. serious cardiovascular or cerebrovascular diseases, severe liver or kidney dysfunction, serious and uncontrolled systemic infections or other contraindications, or any contraindications to radiotherapy, and some comorbidities should be re-evaluated after symptomatic treatment; 4. any active immune system disease or related history; 5. systemic immunosuppressive drugs are expected to be used during the study; 6. a history of severe uncontrollable central nervous system diseases or mental disorders, which may hinder the signing of informed consent or treatment compliance; 7. other important medical or physiological conditions (such as pregnancy or breastfeeding status); 8. patients who are known to be allergic to the drugs used in this study; 9. patients refuse or are unable to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse event rate | 6 weeks | The proportion of treatment-related toxicities cases to the total evaluable cases, assessed according to CTCAE 5.0 criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | 6 weeks | Proportion of patients whose tumor volume has shrunk to a predetermined value and can maintain the minimum time limit. |
| Disease control rate | 6weeks | Proportion of patients who achieved remission (PR+CR) or stable lesion (SD) after treatment. |
Countries
China
Contacts
Primary ContactGuangying Zhu, M.D.
Outcome results
None listed